AgomAb Therapeutics NV (NASDAQ:AGMB) Short Interest Update

AgomAb Therapeutics NV (NASDAQ:AGMB) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 755,022 shares, an increase of 74.3% from the April 15th total of 433,265 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average daily volume of 172,021 shares, the days-to-cover ratio is currently 4.4 days.

AgomAb Therapeutics Price Performance

NASDAQ AGMB opened at $10.56 on Tuesday. AgomAb Therapeutics has a fifty-two week low of $9.00 and a fifty-two week high of $17.45. The business has a 50 day moving average of $11.67.

Analyst Ratings Changes

A number of analysts have recently commented on AGMB shares. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target for the company. Morgan Stanley assumed coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price target for the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Finally, Leerink Partners assumed coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AgomAb Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.